Company: CDLX
Filing Date: 2025-03-12
Form Type: 10-K
Source: 0001666071-25-000034
Chunk: 122

Company: Cardlytics, Inc.
Filing Date: 2025-03-12
Form: 10-K
Item: Item 8
Chunk 122
---
,341 7,310 Intangible assets, net11,371 35,003 Goodwill159,429 277,202 Capitalized software development costs, net33,341 24,643 Other long-term assets, net1,650 2,735 Total assets$392,711 $574,144 Liabilities and stockholders' equityCurrent liabilities:Accounts payable$3,689 $4,425 Accrued liabilities:Accrued compensation5,494 11,662 Accrued expenses7,175 9,587 Partner Share liability32,479 48,867 Consumer Incentive liability45,513 52,678 Deferred revenue2,154 2,405 Short-term debt45,863 — Current operating lease liabilities2,025 2,127 Current contingent consideration4,563 39,398 Total current liabilities148,955 171,149 Long-term liabilities:Convertible senior notes, net167,729 227,504 Line of credit— 30,000 Long-term deferred revenue— 67 Long-term operating lease liabilities6,034 6,391 Long-term contingent consideration— 4,162 Other long-term liabilities— 73 Total liabilities322,718 439,346 Commitments and contingencies (Note 13)Stockholders’ equity:Common stock, $0.0001 par value—100,000 shares authorized and 51,257 and 39,728 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively10 9 Additional paid-in capital1,366,958 1,243,594 Accumulated other comprehensive income3,601 2,467 Accumulated deficit(1,300,576)(1,111,272)Total stockholders’ equity69,993 134,798 Total liabilities and stockholders’ equity$392,711 $574,144 

See notes to the consolidated financial statements64

CARDLYTICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except per share amounts)

 Year Ended December 31, 202420232022Revenue$278,298 $309,204 $298,542 Costs and expenses:Partner Share and other third-party costs127,761 150,578 155,507 Delivery costs29,